What is the current Price Target for the Cresud SA Sponsored ADR stock?

The average Cresud SA Sponsored ADR target price is $1.74. This is -83.90% lower than the current stock price. The highest price target is -83.42%, the lowest is -84.05%. 3 Analysts have issued a price target Cresud SA Sponsored ADR 2027 .

How high will the Cresud SA Sponsored ADR stock rise?

No reliable answer can be given as to how high the Cresud SA Sponsored ADR stock will rise. The performance of stocks, including the Cresud SA Sponsored ADR stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Cresud SA Sponsored ADR stock today?

The performance of Cresud SA Sponsored ADR stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Cresud SA Sponsored ADR stock fall?

The decline in Cresud SA Sponsored ADR stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Cresud SA Sponsored ADR Forecast, price target & analysts

$10.87

0.74%

Nasdaq, Oct 27, 10:58 am EDT. Market open.

ISIN

US2264061068

Symbol

CRESY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Food, Beverage & Tobacco

Industry

Food Products

Overview Dividends Analysts Charts Ownership News Strategies

Cresud SA Sponsored ADR Target price 2026 - Analyst rating & recommendation

Cresud SA Sponsored ADR Classifications & Recommendation

Buy

89%

Hold

11%

Cresud SA Sponsored ADR Price Target

Target Price	$1.74
Price	$10.79
Deviation	register free of charge
Number of Estimates	3

	3 Analysts have issued a price target Cresud SA Sponsored ADR 2027 . The average Cresud SA Sponsored ADR target price is $1.74. This is register free of charge lower than the current stock price. The highest price target is register free of charge , the lowest is register free of charge .
	A rating was issued by 9 analysts: 8 Analysts recommend Cresud SA Sponsored ADR to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Cresud SA Sponsored ADR stock has an average upside potential 2027 of register free of charge . Most analysts recommend the Cresud SA Sponsored ADR stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 & 2029

Create a premium account to unlock analyst estimates. Learn more

Annually

	Jun '26	2027 Estimates
Earnings Per Share $	???	???
	???	???
P/E		???

4 Analysts have issued a Cresud SA Sponsored ADR forecast for earnings per share. The average Cresud SA Sponsored ADR EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2026. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2026	$0.18	100.00%
2027	unlock
2028	unlock

Current	71.93	15.55%
2027	unlock
2028	unlock

Cresud SA Sponsored ADR...

Discover more stocks with a high price target

NIO ADR 93.52%

Alibaba Group Holding Ltd 84.85%

Infineon 83.88%

Tencent Holdings Ltd. 74.09%

Siemens Energy 67.71%

Uber Technologies 55.01%

BioNTech SE - ADR 49.14%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now